ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Comparison of pneumococcal conjugate and pneumococcal polysaccharide vaccines used in children in the United States

Comparison of pneumococcal conjugate and pneumococcal polysaccharide vaccines used in children in the United States
  13-valent pneumococcal conjugate vaccine
(PCV13)		 15-valent pneumococcal conjugate vaccine
(PCV15)		 20-valent pneumococcal conjugate vaccine
(PCV20)		 Pneumococcal polysaccharide vaccine
(PPSV23)
Trade name Prevnar 13 Vaxneuvance Prevnar 20 Pneumovax 23
Serotypes contained 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F
Protein carrier CRM197 (a nontoxic mutant of diphtheria toxin) CRM197 (a nontoxic mutant of diphtheria toxin) CRM197 (a nontoxic mutant of diphtheria toxin) None
Adjuvant Aluminum phosphate Aluminum phosphate Aluminum phosphate None
Contains thimerosal? No No No No
Dose 0.5 mL 0.5 mL 0.5 mL 0.5 mL
Route Intramuscular Intramuscular Intramuscular Intramuscular or subcutaneous
Target groups
  • Infants and children ≥6 weeks through 4 years
  • Children 5 through 18 years at increased risk for IPD*
  • Infants and children ≥6 weeks through 4 years
  • Children 5 through 18 years at increased risk for IPD*
  • Infants and children ≥6 weeks through 4 years
  • Children 5 through 18 years at increased risk for IPD*
  • Individuals ≥2 years at increased risk for IPD*
Approved age groups ≥6 weeks ≥6 weeks ≥6 weeks ≥2 years
Number of doses Varies depending on age when series is initiated* Varies depending on age when series is initiated Varies depending on age when series is initiated One or two depending upon risk group*
Recommended schedule 2, 4, 6, and 12 through 15 months 2, 4, 6, and 12 through 15 months 2, 4, 6, and 12 through 15 months

One dose of PPSV23 at age ≥2 years and ≥8 weeks after the last indicated dose of PCV13

A second dose (usually ≥5 years after the first) is recommended for children who are immunocompromised, including those who have sickle cell disease or functional or anatomic asplenia

A second dose is not recommended for immunocompetent children with cochlear implants or chronic illness, including chronic heart disease, chronic lung disease, diabetes mellitus, and cerebrospinal fluid leaks
May be administered with other vaccines? Yes, except PPSV23 Yes, except PPSV23 Yes, except PPSV23 Yes, except PCV13 or PCV15

IPD: invasive pneumococcal disease.

* Refer to UpToDate content on pneumococcal vaccination in children for details.
Graphic 71746 Version 20.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟